Increasing Prevalence Of Cancer Is Driving The Growth Of The Rare Bio Markers Specimen Collection And Stabilization: The Driving Engine Behind Rare Biomarkers Specimen Collection And Stabilization Market Evolution in 2025

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Rare Biomarkers Specimen Collection And Stabilization Market Size Growth Forecast: What to Expect by 2025?
The market encompassing the collection and stabilization of rare biomarkers has experienced swift expansion lately, projected to increase its valuation from $32.01 billion in 2024 to $35.29 billion by 2025, reflecting a compound annual growth rate of 10.3%. This upward trajectory during the past period stems from several factors, including the headway made by the human genome project, mounting endeavors in cancer research, augmented spending on pharmaceutical research and development, the expansion of genomics and proteomics fields, alongside advancements in handling and analyzing biological data through bioinformatics.

How Will the Rare Biomarkers Specimen Collection And Stabilization Market Size Evolve and Grow by 2029?
Anticipation surrounds the rare biomarkers specimen collection and stabilization sector, forecasting robust expansion moving forward, specifically projecting a market valuation of $51.22 billion by 2029, which reflects a steady compound annual growth rate (CAGR) of 9.8%; this upward trajectory is fundamentally driven by the broadening utility of liquid biopsy procedures, heightened public understanding and resulting demand, the escalating preference for minimally invasive methodologies, alongside ongoing biomarker identification efforts within uncommon ailments. Key directional shifts shaping this period involve sophisticated progress in methods for sample preservation, acceleration in both genetic and protein-level investigations, the rise of testing capabilities available immediately where care is delivered, coupled with evolving regulatory frameworks and the integration of superior data analysis tools supported by artificial intelligence.

View the full report here:
https://www.thebusinessresearchcompany.com/report/rare-biomarkers-specimen-collection-and-stabilization-global-market-report

What Drivers Are Propelling the Growth of Rare Biomarkers Specimen Collection And Stabilization Market Forward?
The escalating incidence of cancer is forecast to be a primary catalyst for the expansion of the rare biomarker specimen collection and stabilization sector moving ahead. Cancer, characterized fundamentally by the unrestrained multiplication and dissemination of aberrant cells, is seeing its occurrence augmented due to environmental contamination and behavioral elements like tobacco use and inadequate nutrition, which intensify inherent genetic susceptibilities. Employing advanced techniques for gathering and preserving rare biomarker samples within cancer prevalence research enables superior precision in identifying and tracking particular cancer variations, thereby improving both diagnostic accuracy and treatment strategies. Illustratively, data published in October 2023 by the European Commission, a regulatory authority in Europe, revealed that new cancer diagnoses reached 2.74 million across Europe in 2022, marking a discernible 2.3% jump compared to figures from 2020. Consequently, this heightened frequency of cancer cases directly fuels the advancement of the market dedicated to collecting and stabilizing rare biomarker specimens.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15913&type=smp

Which Emerging Trends Are Transforming the Rare Biomarkers Specimen Collection And Stabilization Market in 2025?
Key players within the rare biomarker specimen collection and stabilization sector are prioritizing the creation of novel technologies, exemplified by a pre-analytical system designed to automatically ready plasma and cellular materials for multiomic liquid biopsy procedures. This automated prep system ensures uniformity and hands-off handling of fresh samples immediately upon blood drawing, facilitating end-to-end processing of whole blood without necessitating proprietary collection tubes or specialized personnel, thus safeguarding the condition of the specimens. A notable demonstration of this trend occurred in May of 2022 when Tethis S.p.A., an Italian biotech firm, introduced its See.d system, which stands as the inaugural fully automated, standardized pre-analytical solution offering distinct capabilities like meticulous sample management, effective isolation of plasma destined for cellular components, and the immobilization of leukocytes onto specialized SmartBioSurface slides. Furthermore, the system incorporates an objective sample stability assessment mechanism through a dedicated quality control scoring feature, a methodology that permits the consistent scoring of resultant proteomics and metabolomics datasets to ascertain the temporal stability of both plasma and serum samples.

What Are the Key Segments in the Rare Biomarkers Specimen Collection And Stabilization Market?
The rare biomarkers specimen collection and stabilizationmarket covered in this report is segmented -

1) By Type: Circulating Cell Free Deoxyribonucleic Acid (CCFDNA); Circulating Tumor Cells (CTCs); Exosomes or Extracellular Vesicles
2) By Specimen: Serum Or Plasma; Other Specimens
3) By Application: Non-Invasive Prenatal Testing (NIPT); Oncology; Transcriptomics; Pharmacogenomics; Transplant Rejection; Population Screening; Cardiovascular Diseases; Other Applications
4) By End-User: Hospitals; Perinatal Clinics; Public Health Labs; Private Or Commercial Labs; Physician Labs; Research Institutes; Other End-Users

Subsegments:
1) By Circulating Cell Free Deoxyribonucleic Acid (CCFDNA): Plasma CCFDNA; Serum CCFDNA
2) By Circulating Tumor Cells (CTCs): CTCs In Blood; CTCs In Bone Marrow
3) By Exosomes Or Extracellular Vesicles: Exosomes From Plasma; Exosomes From Serum

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=15913&type=smp

Who Are the Key Players Shaping the Rare Biomarkers Specimen Collection And Stabilization Market's Competitive Landscape?
Major companies operating in the rare biomarkers specimen collection and stabilization market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Merck KGaA, Becton dic*kinson and Company, Eurofins Scientific SE, Agilent Technologies Inc., PerkinElmer Inc., Illumina Inc., Charles River Laboratories International Inc., Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN N.V., Miltenyi Biotec GmbH, Natera Inc., Promega Corporation, Myriad Genetics, Hamilton Company, OraSure Technologies Inc., Fluidigm Corporation, Streck Inc., SeraCare, Enzo Biochem Inc., Epigenomics AG, Veridex LLC

What Geographic Markets Are Powering Growth in the Rare Biomarkers Specimen Collection And Stabilization Market?
North America was the largest region in the rare biomarkers specimen collection and stabilization market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare biomarkers specimen collection and stabilization market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15913

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.